Earnings
Schrödinger Lifts 2026 Software And Drug Discovery Outlook After A Structure Therapeutics Milestone
Third-quarter revenue rose 19% to $64.5 million, but the net loss widened to $37.7 million from $32.8 million.
SDGR
Schrodinger (SDGR) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Schrodinger's AI Co-Scientist Bunsen Now Handles About 80% Of Its Internal Heavy Calculations
The software maker also raised 2026 guidance, with drug discovery revenue now seen at $75 million to $85 million.
SEC Filings
Schrödinger Burned $96.5 Million In Nine Months While Its Contracted Backlog Shrank
The drug-software maker raised its 2026 outlook even as operating cash swung from $30.0 million generated to $96.5 million used.